RECOGNISING ACHIEVEMENT
GCE

## Human Biology

Advanced Subsidiary GCE
Unit F222: Growth, Development and Disease

## Mark Scheme for June 2013

OCR (Oxford Cambridge and RSA) is a leading UK awarding body, providing a wide range of qualifications to meet the needs of candidates of all ages and abilities. OCR qualifications include AS/A Levels, Diplomas, GCSEs, Cambridge Nationals, Cambridge Technicals, Functional Skills, Key Skills, Entry Level qualifications, NVQs and vocational qualifications in areas such as IT, business, languages, teaching/training, administration and secretarial skills.

It is also responsible for developing new specifications to meet national requirements and the needs of students and teachers. OCR is a not-for-profit organisation; any surplus made is invested back into the establishment to help towards the development of qualifications and support, which keep pace with the changing needs of today's society.

This mark scheme is published as an aid to teachers and students, to indicate the requirements of the examination. It shows the basis on which marks were awarded by examiners. It does not indicate the details of the discussions which took place at an examiners' meeting before marking commenced.

All examiners are instructed that alternative correct answers and unexpected approaches in candidates' scripts must be given marks that fairly reflect the relevant knowledge and skills demonstrated.

Mark schemes should be read in conjunction with the published question papers and the report on the examination.

OCR will not enter into any discussion or correspondence in connection with this mark scheme.

Annotations

| Annotation | Meaning |
| :---: | :---: |
| $\checkmark$ | correct response |
| 3 | incorrect response |
| [-] $\square^{1}$ | benefit of the doubt |
| 200 | benefit of the doubt not given |
| [LET | error carried forward |
| - | information omitted |
| 모 | ignore |
| $\square \square$ | reject |


| Question |  |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | (a) | (i) | box drawn around, A and T/T and A/G and C/C and G ; | 1 | The outline must only include the bases. <br> DO NOT CREDIT if sugar(s) and/or phosphate(s) are included <br> ACCEPT if more than one pair is correctly identified |
|  |  | (ii) | idea that makes sure, DNA / it, replicated, accurately / correctly ; <br> reduces chances of mutation / AW ; <br> AVP; | 2 | ACCEPT <br> no mistakes during DNA replication base sequence must stay the same (DNA) replicates to make identical copies <br> IGNORE refs to cancer <br> e.g. idea that mRNA transcribed correctly correct polypeptide chain / protein (for correct function) |
|  | (b) |  | idea that codes for, growth factors / cyclins / cell cycle control protein ; <br> can be, mutated / changed, into, a cancer causing gene / oncogene / AW ; <br> idea that switched on by, growth factors ; | 1 | IGNORE reference to transcription factors as this is too general <br> IGNORE 'it switches on other genes' unqualified |


| Question |  | Answer |  | Guidance |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (c) | (i) | similarities <br> incidence in both males and females increases, with age <br> OR <br> same incidence at 60-62 (cross over point) <br> OR <br> no incidence before 20 for both ; <br> differences <br> up to age 60-62 females have a higher incidence than <br> males/ AW <br> OR <br> after age 60-62 males have a higher incidence / AW <br> OR <br> between 65 and70 incidence in females stays constant <br> OR <br> a correct comparison between males and female incidence for a given age ; <br> pair of comparative figures in support (similarity or difference) ; | $3$ | age (years) | incidence of melanoma per 100000 |  |
|  |  |  |  |  | male | female |
|  |  |  |  | 10 | 0 | 0 |
|  |  |  |  | 15 | 0 | 0 |
|  |  |  |  | 20 | 1 | 3 |
|  |  |  |  | 25 | 2 | 5 |
|  |  |  |  | 30 | 5 | 10 |
|  |  |  |  | 35 | 7 | 13 |
|  |  |  |  | 40 | 10 | 18 |
|  |  |  |  | 45 | 13 | 20 |
|  |  |  |  | 50 | 17 | 22 |
|  |  |  |  | 55 | 22 | 25 |
|  |  |  |  | 60 | 28 | 30 |
|  |  |  |  | 65 | 40 | 34 |
|  |  |  |  | 70 | 45 | 34 |
|  |  |  |  | 75 | 58 | 40 |
|  |  |  |  | 80 | 60 | 43 |
|  |  |  |  | ACCEPT reference to any two different ages e.g. between 20 and 60. <br> CREDIT reverse argument |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  | incidence with units for each gender for a stated age OR for two different ages for the same gender with incidence units. |  |  |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: |
|  | (ii) | similarity <br> idea that (as age increases) there has been more, exposure to UV / time in sun ORA <br> OR <br> idea that immune system weakens with age <br> OR <br> DNA repair mechanism impaired with ageing <br> OR <br> accumulation of mutations with age <br> OR <br> less efficient apoptosis ; <br> differences <br> idea that younger females, more exposure, to UV / sun <br> OR <br> idea that older males, more exposure, to UV / sun ; | 2 | IGNORE reference to smoking / carcinogens / menopause / female hormones <br> differences <br> ACCEPT descriptions which imply an increased exposure to sunlight e.g. older women more likely to use sun cream OR more older men are bald OR more younger women use sun beds |
| (d) | (i) | (receptors are) protein(s) / glycoprotein(s) ; <br> (cell surface membrane has) complementary / specific, receptors/ binding sites ; | 2 | IGNORE ref to active sites <br> ACCEPT a description of complementary e.g. matching shape or shapes that fit together |
|  | (ii) | idea that (when) no growth factors bound / protein 1 not activated, pathway still active ; <br> protein 3 / 4 continuously, <br> activated / stimulated / signalled ; | 2 |  |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: |
| (e) | (i) | idea that drugs will only, bind to / inactivate / be complementary to , the altered (BRAF) protein ; <br> drug binds to specific points in amino acid sequence; <br> can only target one step in this cascade <br> OR <br> will have no effect on normal cells ; | 2 | DO NOT CREDIT reference to protein unqualified IGNORE reference to inhibition |
|  | (ii) | active site , changed/blocked; <br> substrate will no longer bind ; <br> no , enzyme substrate complexes/products , formed ; | 2 | IGNORE ‘acts as an inhibitor' <br> ACCEPT drug / inhibitor, binds to active site <br> IGNORE growth factors (as substrate) <br> ACCEPT forms an enzyme-inhibitor complex |


| Question |  | Answer | Marks | Guidance |
| :--- | :--- | :--- | :--- | :--- | :--- |
| (f) | (i) | $\begin{array}{l}\text { idea of a large number of, patients / AW ; } \\ \text { compare with, commonly used / best available treatment ; } \\ \text { done to establish any (common) side effects ; }\end{array}$ | 2 | DO NOT CREDIT people unqualified |
| IGNORE reference to placebo |  |  |  |  |$]$| (ii) |
| :--- |
| idea that recruit patients / AW ; <br> people allocated to one of two groups ; <br> method of randomisation ; |


| Question |  |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 2 | (a) | (i) | starts, slowly / gradually; lasts for a long time ; rarely cured ; | 2 | ACCEPT slow onset <br> ACCEPT long term <br> ACCEPT no cure <br> IGNORE ref to severity or fatal consequences or treatment |
|  |  | (ii) | coronary heart disease (CHD) / angina ; atherosclerosis / arteriosclerosis ; diabetes ; (osteo)arthritis ; osteoporosis ; motor neurone (disease) ; multiple sclerosis ; Parkinson's (disease) ; Alzheimer's (disease) ; Kidney failure ; AVP ;; | 2 | Mark the first answer on each prompt line. If the answer is correct and an additional answer is given that is incorrect or contradicts the correct answer then = $\mathbf{0}$ mark <br> DO NOT CREDIT emphysema/asthma <br> DO NOT CREDIT references to infections or genetic diseases |
|  | (b) | (i) | idea that there are more young people in India (than UK) / more elderly people in UK (than in India) ; <br> age is a variable that must be controlled ; <br> idea that a valid / AW, comparison / conclusion can be made, between, countries / genders ; <br> idea that (different / some) respiratory diseases are more common, in different age groups ; | 2 | IGNORE ref to accurate or reliable comparisons <br> ACCEPT a description e.g. 'you are more likely to get respiratory diseases when you are older' or 'some respiratory diseases are more common at certain ages' 'Asthma is more common in children than in older people' |


| Question | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: |
| (ii) | 51 (\%); ; | 2 | Correct answer = $\mathbf{2}$ marks even if no working shown <br> If answer incorrect <br> CREDIT 1 mark for correct working $\frac{942}{1851} \times 100$ <br> If answer not rounded CREDIT 1 mark for unrounded answer eg 50.9, 50.89, 50.891 |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: |
|  | (iii) | DALYs higher in India <br> more people smoke; <br> reason why air pollution is worse in India; <br> consequence of poverty qualified ; <br> 2 max <br> There is a bigger difference between men and women in India than there is in the UK because, in India, men more exposed to pollutants at work than women ; <br> There is a bigger difference between men and women in India than there is in the UK because, in India, women/female children less valued ; | 3 | CREDIT reverse argument for UK <br> e.g. more use of coal (in home) or higher levels of traffic <br> e.g. can't afford, treatment / health care / adequate diet <br> CREDIT same argument for smoking <br> Look for an example e.g. boys likely to be fed more than girls or more likely to be treated with antibiotics |
| (c) | (i) | (smooth) muscle contracts / goes into spasm ; (bronchiole) lumen , constricted/narrowed/ becomes smaller ; <br> (bronchiole) wall / lining becomes, swollen ; <br> lining / membrane, becomes inflamed / more folded ; more mucus produced / mucus builds up ; | 3 | Mark the first answer on each prompt line. If the answer is correct and an additional answer is given that is incorrect or contradicts the correct answer then = $\mathbf{0}$ mark <br> CREDIT bronchoconstriction |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :--- | :---: | :---: |
| (c) | (ii) | for either <br> taken by , inhaler / tablet / syrup / orally ; <br> steroids <br> may be injected ; <br> reduce the inflammation (in the airways); <br> work slowly / long term effect ; <br> beta-agonists <br> bronchodilators ; <br> relax muscles (in airways); <br> work, quickly / immediately ; | CREDIT once only |  |


| Ques | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: |
| (d) | idea of to reduce /discourage / ban, smoking ; <br> idea of improve air quality, qualified ; <br> idea of reduce exposure to pollution in, factories/places of work ; | 2 | Mark as prose <br> e.g. more education on smoking dangers / increase cigarette prices / increase age restriction on buying cigarettes / ban smoking in public places <br> e.g. encouraging use of another fuel instead of solid fuel / ref to use of public transport / one car per family <br> e.g. offer masks in factories / limit exposure time / better health and safety regulations |
|  | Total | 21 |  |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: |
| 3 (a) | (i) | Klinefelter's (syndrome) ; | 1 | ACCEPT phonetic spelling |
|  | (ii) | an extra chromosome / 47 chromosomes <br> OR <br> 2 X (chromosomes) and a Y ; | 1 |  |
| (b) |  | 1 culture cells ; <br> 2 (chemical added to) stimulate cells to divide / undergo mitosis; <br> 3 stop , spindle being formed / division at beginning of metaphase; <br> 4 (by) adding colchicine ; <br> 5 (before staining) (dilute) salt solution added (to burst cells) ; <br> 6 (before sorting) chromosomes / genetic material / <br> DNA, stained ; <br> 7 (finally) chromosomes sorted into pairs; | 5 | IGNORE 'stain the cell' or 'stain the sample' IGNORE refs to photographs |
| (c) | (i) | (non-disjunction) lower left pair of arrows indicated <br> OR <br> middle left cell ; <br> (diploid) <br> top cell labelled ; | 2 |  |



| Question |  |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 4 | (a) |  | endothelium ; <br> lumen ; <br> atheroma; <br> muscle ; <br> oxygen ; | 5 | ACCEPT tunica intima, tunica interna DO NOT CREDIT epithelium <br> ACCEPT plaque <br> IGNORE ref. to glucose |
|  | (b) |  | ```pain / AW, in chest ; pain spreading to, neck / arms / jaws / stomach / back ; light headed / dizzy / faint / short of breath ; vomiting / nauseous; irregular / abnormal, pulse ; sense of doom ; (more) sweating ; skin, white or grey / lips become blue;``` | 2 | e.g. tightness |
|  | (c) | (i) | no pulse / heart not beating; unconscious; skin, white or grey / lips become blue ; | 2 | IGNORE ref to breathing |



| Question |  |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 5 | (a) | (i) | MMR ; | 1 |  |
|  |  | (ii) | diphtheria; <br> tetanus ; <br> whooping cough / pertussis; <br> polio ; <br> influenza; | 4max | CREDIT first four answers only. If the answer is correct and an additional answer is given that is incorrect or contradicts the correct answer then = $\mathbf{0}$ mark ACCEPT phonetic spelling throughout <br> ACCEPT flu |
|  | (b) | (i) | 1 (booster / pathogen produces) more / large numbers of, memory cells ; <br> how vaccine protects <br> 2 antigen injected / taken into body; <br> 3 primary response / described; <br> 4 produces (antibodies and) memory cells; <br> 5 specific to, antigen / pathogen ; <br> why more than one dose given <br> 6 (booster) causes a, secondary response ; <br> 7 memory cells, activated / AW, faster ; immune because <br> 8 the child is, infected with the pathogen / AW , they don't get ill / AW ; <br> 9 (because) large(r) number of antibodies produced (when infected by pathogen); <br> 10 so pathogen destroyed (faster); <br> QWC for balanced account ; | 9 | AWARD in context of booster or pathogen only <br> e.g. antigen recognition, clonal selection, clonal expansion <br> MP1 plus1 MP from 2-7 plus 1 MP from $8-10$ |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: |
|  | (ii) | before 2 months child may (still) have antibodies from mother (which would neutralise vaccine) ; <br> disease more severe in young children / AW ; <br> younger children more at risk from complications of disease / AW ; | 1 | CREDIT correct reference to (natural) passive immunity |
|  | (iii) | risk of side effects / named side effect ; | 1 | for example: high temperature, vomiting, diarrhoea, mild symptoms of disease, rash / fits /autism / illness |
| (c) |  | insufficient protein (in diet) / AW ; <br> unable to make, antibodies / memory cells / lymphocytes ; <br> because amino acids not available ; | 2 |  |
|  |  | Total | 18 |  |


| Question |  | Answer | Marks | Guidance |
| :---: | :---: | :---: | :---: | :---: |
| 6 | (a) | cells, differentiate/become specialised / described ; forming groups of cells called tissues; named tissue in respiratory system ; <br> (different) tissues , form organs ; <br> named organ in respiratory system ; | 4 | ciliated / squamous epithelium, alveolar, smooth muscle, cartilage, connective tissues DO NOT CREDIT in the context of cells <br> lung, trachea, bronchus, bronchiole, |
|  | (b) | ```iron; calcium / Vitamin K ; calcium / Vitamin D / phosphate; phosphate ; Vitamin C ;``` | 5 | ACCEPT correct symbol for element or ion e.g. $\mathrm{Ca} / \mathrm{PO}_{4}{ }^{2-}$ ACCEPT phosphorus for phosphate <br> ACCEPT Pi |
|  | (c) | cannot be synthesised by the body / must be present in the diet ; | 1 |  |
|  |  | Total | 10 |  |

OCR (Oxford Cambridge and RSA Examinations)
1 Hills Road
Cambridge
CB1 2EU
OCR Customer Contact Centre
Education and Learning
Telephone: 01223553998
Facsimile: 01223552627
Email: general.qualifications@ocr.org.uk
www.ocr.org.uk

For staff training purposes and as part of our quality assurance programme your call may be recorded or monitored

Oxford Cambridge and RSA Examinations is a Company Limited by Guarantee Registered in England
Registered Office; 1 Hills Road, Cambridge, CB1 2EU


Registered Company Number: 3484466
OCR is an exempt Charity
OCR (Oxford Cambridge and RSA Examinations)
Head office
Telephone: 01223552552
Facsimile: 01223552553

